Market Intelligence, Clinical Progress, and High-Purity Reagents for Complement-Mediated Renal/Ocular Diseases and Immuno-Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CFH drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CFH Full-Length Native Protein 20 SCR domains, High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CFH Products |
| Mutant Panel | CFH Y402H / I62V Variants AMD-risk alleles for pharmacogenomic studies. HEK293 Expressed (Native Glycosylation). |
View CFH Products |
| Specificity Controls | CFHR1 / CFHR3 / CFHR5 Proteins Homologous family members for cross-reactivity screening. |
View CFHR1 Products |
| Gene Delivery | CFH Promise-ORF / Lentivirus Full-length ORF for stable overexpression cell lines. |
View CFH Products |
| Benchmark Ab | Anti-CFH Neutralizing Antibody Recombinant positive control for functional blockade assays. |
View CFH Products |
| Validator | CFH siRNA Set For knockdown and specificity verification in cell-based assays. |
View CFH Products |
| Pathway Partner | C3 (Complement Component 3) Primary ligand for CFH regulatory function. |
View C3 Products |
| Pathway Partner | CFI (Complement Factor I) Cofactor for CFH-mediated C3b cleavage. |
View CFI Products |
| Pathway Partner | CFB (Complement Factor B) Synergistic target for alternative pathway modulation. |
View CFB Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| CFHR1/CFHR3 Cross-Reactivity (High homology 45-50% identity) | CFHR1/CFHR3/CFHR5 Homolog Panel (>95% purity) for strict specificity validation by SPR/BLI |
| AMD Risk Variant Function (Y402H polymorphism) | Sequence-verified Y402H mutant with native glycosylation pattern for binding affinity comparisons |
| Species Translation (Human to Cyno/Mouse) | Human/Mouse/Cyno CFH ortholog proteins available with matched production standards |
| False Positives in Binding Assays | Validated siRNA and neutralizing antibodies included for specificity controls |
Live CFH R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The CFH therapeutic landscape is bifurcating between replacement strategies for complement-mediated renal and ocular diseases (aHUS, C3G, dry AMD) and inhibitory approaches for immuno-oncology. Following setbacks in recombinant protein replacement (GEM103 discontinuation), the field is pivoting toward gene therapy delivery (AAV-CFH) for durable expression in rare diseases, while oncology programs leverage monoclonal antibodies to block CFH-mediated tumor protection and unleash complement-dependent cytotoxicity (CDC). The next wave of R&D focuses on SCR-domain selective modulation to preserve host regulation while targeting pathological surfaces. Localized delivery to the eye for geographic atrophy (GA) and systemic regulation for atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy remain key areas, with gene therapy (e.g., Gyroscope Therapeutics) and small-molecule pathway inhibitors (e.g., Novartis) adding diversity to the pipeline.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Recombinant CFH Protein | Gemini (Discontinued), Academic Consortia | aHUS, Dry AMD | Full-length SCR1-20 integrity assay (Need high-purity, endotoxin-controlled native protein) |
| Anti-CFH Antibody | Janssen, BioMarin (Early) | Solid Tumors (IO) | CFHR1/CFHR3 specificity screen (Need homolog panel to avoid off-target binding) |
| Gene Therapy (AAV-CFH) | 4D Molecular, Asklepios | C3G, aHUS | Functional potency vs Y402H variants (Need mutant proteins for transgene efficacy) |
| Peptide Mimetics (SCR 19-20) | Amyndas, TBD | Alternative pathway dysregulation | C3b/Heparin competitive binding (Need purified SCR domains) |